Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00759668 · ClinicalTrials.gov registry record · NA

Visual Function and Patient Satisfaction After Bilateral Implantation of AcrySof Natural ReSTOR (Model SN60D3) or AcrySof Natural Monofocal (Model SN60AT)

A NA study of Cataract, sponsored by Alcon Research.

Completed
Registry status
NA
Development phase
35
Enrollment target
1
Study location

NCT00759668 is a NA study of Cataract that has completed, run by Alcon Research. The registered enrollment target is 35 participants, below the 228-participant average among 83 other Cataract trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00759668, a NA study of Cataract, has completed, sponsored by Alcon Research.

COMPLETED
Registry status
NA
Development phase
35 participants
Enrollment target
1
Study location

Study Summary

The purpose of the study is: * to compare visual parameters (Subjective refraction and Visual Acuity (VA)) and safety (tilt, decentration and posterior chamber opacification (PCO)) in a prospective series of 40 patients after bilateral implantation of AcrySof Natural ReSTOR (Model SN60D3) or AcrySof Natural Monofocal (Model SN60AT) * to assess patient satisfaction before and after implant

Conditions Studied

Interventions

  • DEVICE Acrysof Natural ReSTOR SN60D3
  • DEVICE Acrysof Natural Monofocal SN60AT

Study Locations (1)

Texas

  • Contact Alcon Call Center for Trial Locations - Fort Worth

Trial Details

FieldValue
Enrollment Target 35 participants
Start Date 2007-05
Est. Completion 2009-09
Phase NA

Sponsor

Alcon Research

275 total trials

What the Registry Record Tells You About NCT00759668

The ClinicalTrials.gov registry entry for NCT00759668 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 228-participant average among 83 other Cataract trials with a reported enrollment target (85% lower). The listed sponsor is Alcon Research, which has 275 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Cataract appearing as the primary indexed condition, and to 2 interventions - of which Acrysof Natural ReSTOR SN60D3 is the first listed.

NCT00759668 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT00759668 about?

NCT00759668 is a clinical study titled "Visual Function and Patient Satisfaction After Bilateral Implantation of AcrySof Natural ReSTOR (Model SN60D3) or AcrySof Natural Monofocal (Model SN60AT)". The purpose of the study is: * to compare visual parameters (Subjective refraction and Visual Acuity (VA)) and safety (tilt, decentration and posterior chamber opacification (PCO)) in a prospective series of 40 patients after bilateral implantation of AcrySof Natural ReSTOR (Model SN60D3) or AcrySo...

What is the current status of trial NCT00759668?

This trial is currently completed. It is a NA study. The enrollment target is 35 participants. The study started on 2007-05. Estimated completion is 2009-09.

What conditions does trial NCT00759668 study?

This clinical trial studies the following conditions: Cataract.

What interventions are being tested in trial NCT00759668?

The interventions under investigation include: Acrysof Natural ReSTOR SN60D3 (DEVICE), Acrysof Natural Monofocal SN60AT (DEVICE).

Who is sponsoring clinical trial NCT00759668?

This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00759668 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cataract

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.